NEGLECTED DISEASE RESEARCH & DEVELOPMENT: THE EBOLA EFFECT
POLICY CURES

• An independent non-profit research group

• Innovative ideas and rigorous analysis

• Focussed on R&D for neglected diseases of the developing world
G-FINDER
OVERVIEW

- Annual survey of global neglected disease R&D funding
- Neutral, comparable, comprehensive analysis
- Commissioned by the Bill & Melinda Gates Foundation
G-FINDER
SCOPE & METHODOLOGY

- 35 neglected diseases (Ebola included)
- 142 product areas
- All R&D stages
- Data from 198 organisations
- Over 9,300 entries
- Reported in 2014 USD
Findings
OVERALL

$3,377m  Investment in neglected
disease R&D in 2014
Findings

OVERALL

Total funding 2007-2014 (US$, billions)

<table>
<thead>
<tr>
<th>Year</th>
<th>Funding (US$ billions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>2.7</td>
</tr>
<tr>
<td>2008</td>
<td>3.0</td>
</tr>
<tr>
<td>2009</td>
<td>3.3</td>
</tr>
<tr>
<td>2010</td>
<td>3.1</td>
</tr>
<tr>
<td>2011</td>
<td>3.1</td>
</tr>
<tr>
<td>2012</td>
<td>3.2</td>
</tr>
<tr>
<td>2013</td>
<td>3.0</td>
</tr>
<tr>
<td>2014</td>
<td>3.2</td>
</tr>
</tbody>
</table>

$150m increase
Findings

DISEASES

2014 disease changes

- Ebola: $165m (+11%)
- Malaria: $56m (+14%)
- Kinetoplastids: $16m (+2.3%)
- TB: $13m (+16%)
- Dengue: $12m
- Bacterial Pneumonia & meningitis
- Diarrhoeal diseases:
  - $15m (-20%)
  - $18m (-9.4%)
## Findings

### TOP FUNDERS

<table>
<thead>
<tr>
<th>Funder</th>
<th>2014 (US$ millions)</th>
<th>2014 % of total</th>
</tr>
</thead>
<tbody>
<tr>
<td>US NIH</td>
<td>1,298</td>
<td>38</td>
</tr>
<tr>
<td>Aggregate industry</td>
<td>534</td>
<td>16</td>
</tr>
<tr>
<td>Gates Foundation</td>
<td>531</td>
<td>16</td>
</tr>
<tr>
<td>Wellcome Trust</td>
<td>128</td>
<td>4</td>
</tr>
<tr>
<td>European Commission</td>
<td>126</td>
<td>4</td>
</tr>
<tr>
<td>US DOD</td>
<td>96</td>
<td>3</td>
</tr>
<tr>
<td>UK DFID</td>
<td>81</td>
<td>2</td>
</tr>
<tr>
<td>USAID</td>
<td>77</td>
<td>2</td>
</tr>
<tr>
<td>Inserm</td>
<td>54</td>
<td>2</td>
</tr>
<tr>
<td>UK MRC</td>
<td>50</td>
<td>1</td>
</tr>
<tr>
<td>Indian ICMR</td>
<td>33</td>
<td>1</td>
</tr>
<tr>
<td>Australian NHMRC</td>
<td>30</td>
<td>1</td>
</tr>
</tbody>
</table>
Findings

Largest industry contribution ever

FUNDERS

Private 16%
Philanthropic 20%
Public 64%
Findings
FUNDERS

2014 funding change – with Ebola

2014 funding change – without Ebola

Private

Public

Philanthropic

Private

Public

Philanthropic

$98m (+28%)

$64m (+18%)

-$62m (-3.1%)

$55m (+2.7%)

-$3.2m (-0.5%)

-$15m (-2.3%)

Discussion

EBOLA

$165m rapidly mobilised for Ebola R&D
Discussion
PUBLIC FUNDING

-$221m drop in US Government non-Ebola R&D funding since 2009
Discussion

INDUSTRY

Industry investment 2007-2014

$51m
2014 malaria R&D increase from industry

$33m
2014 HIV/AIDS R&D increase from industry
Discussion
PDP FUNDING

$42m increase in 2014
Download the report at www.policycures.org/g-finder2015.html